Kinase Chemistry – Just a year and a half behind the times.


Posted by kinasepro on December 1, 2006

Hi Scripps, nice indolinones. I don’t generally hit academic patent apps, but for this one… Well for this one – at least someone out there knows why this is a good one to put up.

…Enhanced and unexpected drug like properties that advantageously distinguishes this class of compounds over the known… yada yada yada

alpha-OH > beta-OH

got amid?

To get a patent app. like this accepted where you’re basically saying: yah we know we’re super close to other known stuff, but this stuff is better because of X. You generally have to provide details about X, in this case which of those drug like properties were improved? While I didn’t go over this one with a fine-toothed comb, I didn’t see any PK, CYP, or even solubility data published 😦

More plz

3 Responses to “WO2006127961”

  1. I guess the freedom to operate argument doesn’t matter with these compounds anymore, with Pfizer (aka Sugen, whose patent these are probably closest to?) having just done a deal with Scripps to commercialise their research,0,5950303.story?coll=sfla-news-palm

  2. milkshake said

    “Propositions under 7: What we cannot speak about we must pass over in silence”

  3. kinasepro said

    Scripps will receive $20 million a year in unrestricted payments.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: